EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy

Qi Gao iD, Xueyan Chen, Sindhu Cherian, Mikhail Roshal

Cytometry Part B: Clinical Cytometry · 2023-05 · 104 (3) · 224-242

DOI: 10.1002/cyto.b.22097 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 02.11.2022. Verfasst von Qi Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Plasma Cells, Neoplasms, Plasma Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 145 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flow cytometry has been indispensable in diagnosing B cell lymphoma and plasma cell neoplasms. The advances in novel multicolor flow cytometry have also made this technology a robust tool for monitoring minimal/measurable residual disease in chronic lymphocytic leukemia and multiple myeloma. However, challenges using conventional gating strategies to isolate neoplastic B or plasma cells are emerging due to the rapidly increasing number of antibody therapeutics targeting single or multiple classic B/plasma cell‐lineage markers, such as CD19, CD20, and CD22 in B cells and CD38 in plasma cells. This review is the first of a two‐part series that summarizes the most current targeted therapies used in B and plasma cell neoplasms and proposes detailed alternative approaches to overcome post‐targeted therapy analysis challenges by flow cytometry. The second review in this series (Chen et al.) focuses on challenges encountered in the use of targeted therapy in precursor B cell neoplasms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasma CellsNeoplasms, Plasma CellHumansAntigens, CDFlow CytometryB-LymphocytesNeoplasm, ResidualImmunophenotyping

Stichwörter der Autor:innen

B cell lymphomaflow cytometryminimal/measurable residual diseasemultiple myelomatargeted immunotherapy

Substanzen

Antigens, CD

Autor:innen und Institutionen

  • Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.

ORCID-Profile: Qi Gao

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Gao, Q., Chen, X., Cherian, S., & Roshal, M. (2023). Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy. Cytometry Part B: Clinical Cytometry, 104(3), 224-242. https://doi.org/10.1002/cyto.b.22097

Vancouver

Gao Q, Chen X, Cherian S, Roshal M. Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy. Cytometry Part B: Clinical Cytometry. 2023;104(3):224-242. doi:10.1002/cyto.b.22097

BibTeX
@article{Gao2023,
  author = {Gao, Qi and Chen, Xueyan and Cherian, Sindhu and Roshal, Mikhail},
  title = {Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2023},
  volume = {104},
  number = {3},
  pages = {224--242},
  doi = {10.1002/cyto.b.22097}
}
Kostenlos starten →